Characterization of Binding of Raltegravir to Plasma Proteins

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2013-07-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1128/AAC.00625-13PMID 23856784PMCID PMC3811458
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intracellular Drug Concentrations

  2013cited by this paper
• Divalent Metals and pH Alter Raltegravir Disposition In Vitro

  2012cited by this paper
• Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals

  2011cited by this paper
• Clinical Pharmacokinetic and Pharmacodynamic Profile of the HIV Integrase Inhibitor Elvitegravir

  2011cited by this paper
• Pharmacokinetics of etravirine , raltegravir and darunavir / ritonavir in treatment experienced patients

  2010cited by this paper
• Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.

  2010cited by this paper
• Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action

  2010cited by this paper
• High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.

  2009cited by this paper
• High Concentration of Raltegravir in Semen of HIV-Infected Men: Results from a Substudy of the EASIER-ANRS 138 Trial

  2009cited by this paper
• A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine.

  2009cited by this paper
• Safety, Tolerability, and Pharmacokinetics of Raltegravir After Single and Multiple Doses in Healthy Subjects

  2008cited by this paper
• Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals

  2006cited by this paper
• Determination of Amprenavir Total and Unbound Concentrations in Plasma by High-Performance Liquid Chromatography and Ultrafiltration

  2006cited by this paper
• The pH Dependency of the Binding of Drugs to Plasma Proteins in Man

  2005influential reference
• The binding of HIV-1 protease inhibitors to human serum proteins.

  2003cited by this paper
• Changes in plasma protein binding have little clinical relevance

  2002cited by this paper
• Antiretroviral drug concentrations in semen of HIV-1 infected men

  2001cited by this paper
• Measurement and Analysis of Unbound Drug Concentrations

  1996cited by this paper
• Interindividual variability in the concentrations of albumin and alpha-1-acid glycoprotein in patients with renal or liver disease, newborns and healthy subjects: implications for binding of drugs.

  1992cited by this paper
• Evidence for the fatty acid-induced heterogeneity of the N and B conformations of human serum albumin.

  1985cited by this paper
• pH homeostasis in human lymphocytes: modulation by ions and mitogen

  1984cited by this paper
• Evidence for binding of certain acidic drugs to alpha 1-acid glycoprotein.

  1982cited by this paper
• Evidence for binding of certain acidic drugs to α1-acid glycoprotein

  1982cited by this paper
• A structural transformation in bovine and human plasma albumins in alkaline solution as revealed by rotatory dispersion studies.

  1963cited by this paper

• Pharmacokinetics of dolutegravir, tenofovir and lamivudine during venous-venous extracorporeal membrane oxygenation (VV-ECMO): A case report.

  2026cites this paper
• Total, Unbound, Renal, and Hepatic Clearances of Raltegravir and the Formation and Elimination Clearances of Raltegravir Glucuronide in Pregnant Women

  2023cites this paper
• Management of Drug Interactions with Inducers: Onset and Disappearance of Induction on Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyltransferase 1A1 Substrates

  2023cites this paper
• HIV-1 Integrase Strand Transfer Inhibitors and Neurodevelopment

  2022cites this paper
• Natural products and synthetic analogues against HIV: A perspective to develop new potential anti-HIV drugs.

  2022cites this paper
• Dolutegravir impairs stem cell-based 3D morphogenesis models in a manner dependent on dose and timing of exposure: an implication for its developmental toxicity.

  2021cites this paper
• Pharmacokinetic drug interactions of integrase strand transfer inhibitors

  2021cites this paper
• Development of a simple and rapid method to determine the unbound fraction of dolutegravir, raltegravir and darunavir in human plasma using ultrafiltration and LC-MS/MS.

  2021cites this paper
• Effect of Pregnancy on Unbound Raltegravir Concentrations in the ANRS 160 RalFe Trial

  2020cites this paper
• Pharmacovirological analyses of blood and male genital compartment in patients receiving dolutegravir + lamivudine dual therapy as a switch strategy (ANRS 167 LAMIDOL trial).

  2020cites this paper
• Characteristics of Dolutegravir and Bictegravir Plasma Protein Binding: a First Approach for the Study of Pharmacologic Sanctuaries

  2020cites this paper
• Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS‐163 ETRAL Study

  2019cites this paper
• Determination of dolutegravir's unbound fraction in human plasma using validated equilibrium dialysis and LC-MS/MS methods.

  2018cites this paper
• Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps

  2018cites this paper
• Is the unbound concentration of atazanavir of interest in therapeutic drug monitoring?

  2017cites this paper
• Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors

  2016cites this paper
• Pharmacokinetic study of raltegravir in HIV-infected patients with end-stage liver disease: the LIVERAL-ANRS 148 study.

  2014cites this paper
• Pregnancy influences the plasma pharmacokinetics but not the cerebrospinal fluid pharmacokinetics of raltegravir: a preclinical investigation.

  2014cites this paper
• Raltegravir as antiretroviral therapy in HIV/AIDS

  2014cites this paper